Aslan Pharma: Highest since May IPO as H.C. Wainwright starts with "buy"

Aslan Pharmaceuticals

30/05/2018 17:30

** U.S. listed shares  ASLN.O  of Singapore-based drug
developer up as much as 29.2 pct at $8.85, highest since U.S.
debut
    ** H.C. Wainwright and Co starts coverage with a "buy" 
rating, sets PT at $12, says Aslan is an emerging biopharma co
focused on oncology and inflammatory disorders, cancer types
that are very common in Asia 
    ** Adds that data from such studies are likely to be robust
and indicate drug safety and accurately measure efficacy
    ** Thus allowing Aslan to kill two birds with one stone,
secure regulatory approval in both Asia as well as Western
geographies using the same data sets - H.C. Wainwright  
    ** U.S. listed shares  ASLN.O  rose nearly 26 pct since
early May IPO including session's gains so far

 (Reporting by Shreyashi Sanyal in Bengaluru)
 ((RM: Shreyashi.Sanyal.thomsonreuters.com@reuters.net))